The positive results from the subgroup analysis of nab-Sirolimus presented by Aadi Bioscience indicate a strong potential for the drug in treating advanced malignant PEComa of gynecologic origin. Given that this subgroup accounted for more than half of the patients in the AMPECT study, and the additional data suggesting its potential as a treatment for mTOR-driven gynecologic cancers, investor confidence in AADI may increase. This could lead to a positive short-term impact on AADI's stock price, as the market reacts to the potential for nab-Sirolimus to address a significant unmet medical need.